Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 trial of ADL5747 for postherpetic neuralgia was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• ADL5747

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Postherpetic Neuralgia | Phase 2 | Status: TERMINATED | Results posted: 2015-07-08